EFPIA "did not lobby" for EC medicines move
This article was originally published in Scrip
As pressure grows for a rethink of controversial plans to place pharmaceutical policy under the European Commission's industry directorate, Richard Bergström, head of the European pharmaceutical industry body EFPIA, has said the new arrangement "makes sense" but insisted the federation did not and would not lobby for such a move.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.